|
|||||
|
|
Genetic study of neuregulin 1 and receptor tyrosine-protein kinase erbB-4 in tardive dyskinesia |
|
| Authors: | Clement C Zai Arun K Tiwari Nabilah I Chowdhury Zeynep Yilmaz Vincenzo de Luca Daniel J Müller |
| Institution: | 1. Neurogenetics Section, Tanenbaum Centre for Pharmacogenetics, Molecular Brain Science, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada;2. Department of Psychiatry, University of Toronto, Toronto, ON, Canada;3. Laboratory Medicine and Pathophysiology, University of Toronto, ON, Canada;4. Center of Excellence for Eating Disorders at the University of North Carolina at Chapel Hill, NC, USA;5. Institute of Medical Science, University of Toronto, Toronto, ON, Canada |
| Abstract: | Objectives: Tardive dyskinesia (TD) is a movement disorder that may develop as a side effect of antipsychotic medication. The aetiology underlying TD is unclear, but a number of mechanisms have been proposed.Methods: We investigated single-nucleotide polymorphisms (SNPs) in the genes coding for neuregulin-1 and erbB-4 receptor in our sample of 153 European schizophrenia patients for possible association with TD.Results: We found the ERBB4 rs839523?CC genotype to be associated with risk for TD occurrence and increased severity as measured by the Abnormal Involuntary Movement Scale (AIMS) (P?=?.003).Conclusions: This study supports a role for the neuregulin signalling pathway in TD, although independent replications are warranted. |
| Keywords: | Tardive dyskinesia schizophrenia pharmacogenetics neuregulin 1 (NRG1) receptor tyrosine-protein kinase erbB-4 (ERBB4) |